OKYO Pharma Ltd
urcosimod
neuropathic corneal pain (NCP)
Resolved
356days ago
Phase 2 readout · Jul 16, 2025
What's at stake
Phase 2 trial results for urcosimod in neuropathic corneal pain (NCP) are due Jul 16, 2025. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 14h ago
“Notably, 75% of per-protocol patients treated with 0.05% urcosimod achieved greater than 80% reduction in pain as measured by the Visual Analogue Scale (VAS) after 12 weeks, demonstrating a highly effective treatment profile.”